Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.82 |
| ▸ | KDR | P35968 | 10/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.74 |
| ▸ | RET | P07949 | 4/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.74 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.74 |
| ▸ | ABL1 | P00519 | 3/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.74 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.74 |
| ▸ | PLK4 | O00444 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 2/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | LCK | P06239 | 2/20 | 0.74 |
| ▸ | FYN | P06241 | 2/20 | 0.74 |
| ▸ | LYN | P07948 | 2/20 | 0.74 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.74 |
| ▸ | AXL | P30530 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1532339 | 0.96 | RAF1 (0.77) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL12391532 | 0.95 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10163311 | 0.95 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16620832 | 0.94 | RAF1 (0.74) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL28430251 | 0.94 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL19888730 | 0.94 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL4732730 | 0.92 | RAF1 (0.71) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16628087 | 0.91 | KDR (0.83) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL13458871 | 0.91 | RAF1 (0.70) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL15624828 | 0.91 | RAF1 (1.00) | RAF1EPHX2KDRMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 445/4885KDR 567/4885 |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BRAF, NRAS, RAF1 | RAF1 3/4885EPHX2 87/4885KDR 192/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | RAF1 452/4885EPHX2 419/4885KDR 2141/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 524/4885KDR 456/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | RAF1 3/4885EPHX2 393/4885KDR 558/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 445/4885KDR 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.